Autoimmune hepatitis—clinical presentation, diagnosis, treatment

被引:0
作者
Stättermayer A.F. [1 ]
Halilbasic E. [1 ]
机构
[1] Universitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie, Medizinische Universität Wien, Währinger Gürtel 18–20, Wien
关键词
Antinuclear antibodies; Autoimmune hepatitis; Azathioprine; Immunosuppression; Interface hepatitis; Overlap syndromes; Prednisolone;
D O I
10.1007/s41971-018-0026-x
中图分类号
学科分类号
摘要
Autoimmune hepatitis (AIH) is a rare chronic inflammatory liver disease that affects all age groups and, without adequate treatment, can lead to liver failure. Early diagnosis and treatment are crucial for a favorable prognosis of AIH. However, the diagnosis may be complicated by the heterogeneous spectrum of clinical, laboratory, and histological manifestations. Increased transaminases and immunoglobulin G levels, positive autoantibodies, characteristic morphological changes in liver histology, and finally, good response to immunosuppressive treatment are among the most important diagnostic criteria and should be evaluated if suspected. The goal of therapy should be to achieve complete clinical, biochemical and histologic response. This can be achieved by immunosuppressive therapy with corticosteroids and azathioprine in most of the patients. However, while many patients initially respond well to standard immunosuppressive therapy, side effects or inadequate treatment response continue to be a challenge in the treatment of AIH. This underscores the need for prospective studies for effective alternative treatment. © 2018, Springer Medizin. All rights reserved.
引用
收藏
页码:40 / 48
页数:8
相关论文
共 46 条
  • [11] Stravitz R.T., Lefkowitch J.H., Fontana R.J., Et al., Autoimmune acute liver failure: proposed clinical and histological criteria, Hepatology, 53, pp. 517-526, (2011)
  • [12] Feld J.J., Dinh H., Arenovich T., Et al., Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome, Hepatology, 42, pp. 53-62, (2005)
  • [13] Takahashi H., Zeniya M., Acute presentation of autoimmune hepatitis: does it exist? A published work review, Hepatol Res, 41, pp. 498-504, (2011)
  • [14] Manns M.P., Czaja A.J., Gorham J.D., Et al., Diagnosis and management of autoimmune hepatitis, Hepatology, 51, pp. 2193-2213, (2010)
  • [15] Czaja A.J., Donaldson P.T., Lohse A.W., Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis, Am J Gastroenterol, 97, pp. 413-419, (2002)
  • [16] Lohse A.W., Mieli-Vergani G., Autoimmune hepatitis, J Hepatol, 55, pp. 171-182, (2011)
  • [17] Boberg K.M., Chapman R.W., Hirschfeld G.M., Et al., Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue, J Hepatol, 54, pp. 374-385, (2011)
  • [18] Muratori P., Granito A., Quarneti C., Et al., Autoimmune hepatitis in Italy: the Bologna experience, J Hepatol, 50, pp. 1210-1218, (2009)
  • [19] Al-Chalabi T., Underhill J.A., Portmann B.C., Et al., Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis, J Hepatol, 48, pp. 140-147, (2008)
  • [20] Yasui S., Fujiwara K., Yonemitsu Y., Et al., Clinicopathological features of severe and fulminant forms of autoimmune hepatitis, J Gastroenterol, 46, pp. 378-390, (2011)